Back

Immune modulating drugs and oral anticoagulation in kidney transplant recipients: comparison of direct oral anticoagulants versus antagonist of vitamin-k. results from a multicenter prospective study.

16 April 2023 (09:40 - 10:40)
Organised by:
Congress Presentation Part of: Atrial Fibrillation - Round 1 - Stroke - OAC Oral Anticoagulation EHRA Premium Access EHRA 2023

About the speaker

Photo
Doctor Francesco Santoro

University of Foggia - Faculty of Medecine, Foggia (Italy)

7 More presentations in this session

Presentation thumbnail
5 years incident stroke, heart failure, acute myocardial infarction, and death in patients having undergone atrial fibrillation ablation according to BMI
Doctor J. Toennesen (Gentofte, DK)
Abstract Slides
Presentation thumbnail
Statin use improves the outcomes in patients with atrial fibrillation: A population-based study
Miss J. Huang (Hong Kong, HK)
Abstract Slides
Presentation thumbnail
Morphology-Voltage-P-wave-duration (MVP) score to select patients for continuous atrial fibrillation screening to prevent stroke
Doctor L. Xing (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
The effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a Belgian nationwide cohort study
Mr M. Grymonprez (Gent, BE)
Abstract Slides
Presentation thumbnail
How good is time-in-therapeutic-range defined warfarin treatment compared to standard dose direct oral anticoagulants? Incidence of stroke in atrial fibrillation in a nationwide registry study.
Doctor M. Lehto (Helsinki, FI)
Abstract Slides

Access the full session

Session thumbnail
Atrial Fibrillation - Round 1 - Stroke - OAC

The Event

Event poster

EHRA 2023

16 April 2023 09:40 CET
You may be interested in
thumbnail
Congress Session
Stroke prevention in clinical and subclinical atrial fibrillation
thumbnail
Congress Session
Oral anticoagulation in subclinical atrial fibrillation
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources